CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Beats Estimates By $0.71 EPS

CRISPR Therapeutics (NASDAQ:CRSP) issued its quarterly earnings results on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

CRISPR Therapeutics Trading Up 9.3 %

Shares of CRSP opened at $43.30 on Thursday. The company has a 50-day moving average of $42.06 and a two-hundred day moving average of $46.25. The stock has a market cap of $3.70 billion, a P/E ratio of -15.30 and a beta of 1.67. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CRSP. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday. Finally, TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a report on Wednesday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $75.56.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.